These images are provided for non-commercial use under a Creative Commons License (BY-NC-ND). To license a high resolution version, please contact our image library who will discuss fees, terms and waivers.
Download this imageCreative commons explained - what it means, how you can use our's and other people's content.
Christ seated disputing with the doctors
Printmaker: Rembrandt Harmensz. van Rijn
Method of acquisition: Bequeathed (1816) by Fitzwilliam, Richard, 7th Viscount
Production date: AD 1654
Only State
Support
composed of
laid paper
Plate
Height 95 mm
Width 145 mm
Sheet
Height 98 mm
Width 148 mm
Accession number: 23.K.5-490
Primary reference Number: 80630
Hollstein (Dutch/Flemish): B64
Biörklund/Barnard: BB54-E
Old location number: 38.7.14a
Stable URI
Owner or interested party:
The Fitzwilliam Museum
Associated department:
Paintings, Drawings and Prints
This record can be cited in the Harvard Bibliographic style using the text below:
The Fitzwilliam Museum (2024) "Christ seated disputing with the doctors" Web page available at: https://collection.beta.fitz.ms/id/object/80630 Accessed: 2024-12-27 03:43:10
To cite this record on Wikipedia you can use this code snippet:
{{cite web|url=https://collection.beta.fitz.ms/id/object/80630
|title=Christ seated disputing with the doctors
|author=The Fitzwilliam Museum|accessdate=2024-12-27 03:43:10|publisher=The
University of Cambridge}}
To call these data via our API (remember this needs to be authenticated) you can use this code snippet:
https://collection.beta.fitz.ms/api/v1/objects/object-80630
To use this as a simple code embed, copy this string:
<div class="text-center">
<figure class="figure">
<img src="https://data.fitzmuseum.cam.ac.uk/imagestore/pdp/pdp81/large_23_K_5_490_1_201712_sjc288_dc2.jpg"
alt="Christ seated disputing with the doctors"
class="img-fluid" />
<figcaption class="figure-caption text-info">Christ seated disputing with the doctors</figcaption>
</figure>
</div>
Updates about future exhibitions and displays, family activities, virtual events & news. You'll be the first to know...
